Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthonius de Boer

Showing results (251-260 of 282) with videos related to

Pageof 29
Sort By:
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|December 18, 2010
Genetic variation in the renin--angiotensin system, use of renin--angiotensin system inhibitors and the risk of myocardial infarctionAnke-Hilse Maitland-van der Zee, Diane Bma van Wieren-de Wijer, Anthonius de Boer, et al.
British Journal of Cancer|April 21, 2017
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicityDidier Meulendijks, Linda M Henricks, Bart A W Jacobs, et al.
European Heart Journal|September 14, 2010
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control studyAnkie M Harmsze, Jochem W van Werkum, Jurriën M Ten Berg, et al.
Pharmacogenetics and Genomics|December 29, 2016
Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitorsSeyed H Mahmoudpour, Abirami Veluchamy, Moneeza K Siddiqui, et al.
Scientific Reports|February 3, 2021
Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetesShifteh Abedian, Ali Abbasi, Anthonius de Boer, et al.
Journal of Hypertension|January 17, 2009
Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarctionDiane B M A van Wieren-de Wijer, Anke-Hilse Maitland-van der Zee, Anthonius de Boer, et al.
Pharmacoepidemiology and Drug Safety|May 23, 2009
Reasons for non-response in observational pharmacogenetic researchDiane B M A van Wieren-de Wijer, Anke-Hilse Maitland-van der Zee, Anthonius de Boer, et al.
Pharmacogenomics|October 22, 2009
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial designRianne M F van Schie, M I A Wadelius, Farhad Kamali, et al.
Pharmacogenomics|December 11, 2012
Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance doseRianne M F van Schie, Judith A M Wessels, Talitha I Verhoef, et al.
Pharmacogenetics and Genomics|June 14, 2008
Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variantBas J M Peters, Anke-Hilse Maitland-van der Zee, Bruno H Ch Stricker, et al.
Pageof 29

Showing results (251-260 of 282) with videos related to

Sort By:
Pageof 29
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|December 18, 2010
Genetic variation in the renin--angiotensin system, use of renin--angiotensin system inhibitors and the risk of myocardial infarctionAnke-Hilse Maitland-van der Zee, Diane Bma van Wieren-de Wijer, Anthonius de Boer, et al.
British Journal of Cancer|April 21, 2017
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicityDidier Meulendijks, Linda M Henricks, Bart A W Jacobs, et al.
European Heart Journal|September 14, 2010
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control studyAnkie M Harmsze, Jochem W van Werkum, Jurriën M Ten Berg, et al.
Pharmacogenetics and Genomics|December 29, 2016
Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitorsSeyed H Mahmoudpour, Abirami Veluchamy, Moneeza K Siddiqui, et al.
Scientific Reports|February 3, 2021
Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetesShifteh Abedian, Ali Abbasi, Anthonius de Boer, et al.
Journal of Hypertension|January 17, 2009
Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarctionDiane B M A van Wieren-de Wijer, Anke-Hilse Maitland-van der Zee, Anthonius de Boer, et al.
Pharmacoepidemiology and Drug Safety|May 23, 2009
Reasons for non-response in observational pharmacogenetic researchDiane B M A van Wieren-de Wijer, Anke-Hilse Maitland-van der Zee, Anthonius de Boer, et al.
Pharmacogenomics|October 22, 2009
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial designRianne M F van Schie, M I A Wadelius, Farhad Kamali, et al.
Pharmacogenomics|December 11, 2012
Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance doseRianne M F van Schie, Judith A M Wessels, Talitha I Verhoef, et al.
Pharmacogenetics and Genomics|June 14, 2008
Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variantBas J M Peters, Anke-Hilse Maitland-van der Zee, Bruno H Ch Stricker, et al.
Pageof 29